ArticleJAC-antimicrobial resistance2026
Individualizing beta-lactam dosing in real-world patients: lessons from a pharmacist-led programme implementation and evaluation.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individualized dosing of beta-lactam using serum concentrations is an emerging approach to overcome PK/PD variability in select patients. Herein, we describe a beta-lactam dose individualization programme highlighting successes and challenges. Methods: We conducted a single-centre evaluation of a beta-lactam dose individualization using serum concentration monitoring programme. In September 2023, a pharmacist-driven protocol was implemented at an academic centre as a collaboration between Infectious Diseases, Pharmacy, and the Clinical Laboratory. De-centralized pharmacists ordered serum concentrations for cefepime, meropenem or piperacillin-tazobactam treated patients. Results: Interpretation was conducted using Bayesian software. The drug monitored, treatment indication, model fitness, whether therapy was altered, whether protocols were followed and PK/PD attainment for each patient were recorded. Eighty-two beta-lactam serum levels were ordered in 47 patients between 26 September 2023 and 31 March 2024. Cefepime was most frequently monitored (70.7%). Common treatment indications in monitored patients were hospital-acquired/ventilator-associated pneumonia (25.5%), surgical prophylaxis (12.8%), bone/joint (12.8%) and central nervous system infection (12.8%). Model fitness was good or intermediate in >95% of cases. Dose or agent optimization was possible in 60% of cases, and dose adjustments were made in 34% of cases. Protocol deviations were common (57.4%). Targets of 100% Conclusion: We found that dose optimization was possible in >50% of monitored patients necessitating dose adjustments >33% of the time. Protocol deviations reinforced areas for continued pharmacist and provider education to optimize the use of this targeted intervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.